WASHINGTON, Sept. 30 (Xinhua) -- The Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults, according to a newly published study.
The experimental vaccine, mRNA-1273, was co-developed by researchers at the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and Moderna, Inc. of Cambridge, Massachusetts.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!